Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease
Bradley M. Haverkos(University of Colorado Denver), Steven M. Devine(National Marrow Donor Program), Stacey Brown(Northside Hospital), Mehdi Hamadani(Medical College of Wisconsin), Mary E.D. Flowers(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Amitkumar Mehta(University of Alabama at Birmingham), Deborah M. Stephens(University of North Carolina at Chapel Hill), Parameswaran Hari(Medical College of Wisconsin), Jeffrey Kaplan(University of Colorado Hospital), Robert Lowsky(Stanford University), Leslie A. Andritsos(University of New Mexico), Jonathan A. Gutman(University of Colorado Denver), Philippe Armand(Harvard University), Reid W. Merryman(Harvard University), Abraham S. Kanate(HonorHealth), Veronika Bachanová(University of Minnesota), Timothy S. Fenske(Medical College of Wisconsin), Madan Jagasia(Vanderbilt University Medical Center), Jeffrey Schowinksy(The Medical Center of Aurora), Ayman Saad(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Manali Kamdar(University of Colorado Cancer Center), Ryotaro Nakamura(City Of Hope National Medical Center), Siddhartha Ganguly(University of Kansas Medical Center)
Cited by 8
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k